EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets
The CHMP is holding an extraordinary meeting to discuss the emerging data for the sickle cell disease drug
The company’s decision to withdraw the drug was based on “the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.”
